View Older Stories
-
Mizuho Upgrades LifeMD Inc (LFMD) to Outperform
-
LifeMD Inc (LFMD) PT Raised to $10 at Freedom Capital Markets
-
LifeMD Inc (LFMD) PT Raised to $10 at H.C. Wainwright
-
Cantor Fitzgerald Reiterates Overweight Rating on LifeMD Inc (LFMD) on Momentum Across Offering
-
LifeMD, Inc. (LFMD) Tops Q4 EPS by 3c, provides guidance
-
H.C. Wainwright Reiterates Buy Rating on LifeMD Inc (LFMD)
-
LifeMD adds Novo Nordisk's oral Wegovy pill to telehealth platform
-
LifeMD Inc (LFMD) PT Lowered to $8 at Freedom Capital Markets
-
LifeMD Inc (LFMD) PT Lowered to $9 at H.C. Wainwright
-
LifeMD Inc (LFMD) PT Lowered at KeyBanc Amid Near-Term Headwinds
-
LifeMD Inc (LFMD) Has Multiple Growth Levers Nearing Pivot Point - Cantor Fitzgerald
-
LifeMD Inc (LFMD) PT Lowered to $10 at BTIG
-
LifeMD, Inc. (LFMD) Misses Q3 EPS by 6c
-
LifeMD reduces cash prices for Wegovy and Ozempic to $199 monthly
-
LifeMD sells majority stake in WorkSimpli for $65 million valuation
-
LifeMD offers Ozempic at $499 monthly via Novo Nordisk partnership
-
Survey shows 1/3 of GLP-1 users are lower-income
-
BTIG Remains Positive Hims and Hers (HIMS)
-
LifeMD Inc (LFMD) Stock Undervalued, Says Cantor Fitzgerald
-
Important Notice to Long-Term shareholders of LifeMD, Inc. (LFMD): Grabar Law Office is Investigating Claims on Your Behalf
-
LifeMD Inc (LFMD) PT Lowered to $12 at KeyBanc
-
Increasing unusual put option volume: OPEN LFMD BBIO SNAP PRMB METC SEI CLOV CIEN MSOS
-
LifeMD, Inc. (LFMD) Misses Q2 EPS by 4c, Guidance Misses
-
LifeMD names Shayna Webb Dray as COO, promotes two other executives
-
LifeMD (LFMD) stock rises on continued Wegovy partnership with Novo Nordisk (NVO)
-
LifeMD Inc (LFMD) PT Raised to $18 at BTIG
-
LifeMD, Inc. (LFMD) Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy
-
Cantor Fitzgerald Reiterates Overweight Rating on LifeMD Inc (LFMD)
-
BTIG Reiterates Buy Rating on LifeMD Inc (LFMD)
-
LifeMD, Inc. (LFMD) Tops Q1 EPS by 7c
-
Increasing unusual option volume: TAL OMEX AMCR HPP WW LFMD ATEC ODD HHH
-
LifeMD, Inc. (LFMD) Plans to Expand Affordable Access to Wegovy for Cash-Pay Patients
-
LifeMD (LFMD) Expands Insurance Acceptance to Medicare Beneficiaries for Qualifying Virtual Primary Care, Including in its Weight Loss Programs
-
BofA: 'Weekly GLP-1 TRx growth in March is trending slightly ahead of February'
-
Given contract opportunity Caid stocks likely undervalued, says Cantor Fitzgerald
-
LifeMD Inc (LFMD) PT Raised to $14 at H.C. Wainwright
-
Cantor Fitzgerald Reiterates Overweight Rating on LifeMD Inc (LFMD)
-
KeyBanc on LifeMD Inc (LFMD): 'We Expect Revenue Growth and Margin Expansion'
-
LifeMD, Inc. (LFMD) Tops Q4 EPS by 26c, Offers Guidance
-
LifeMD, Inc. (LFMD) Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound
-
LifeMD, Inc. (LFMD) enters the Behavioral Health Market
-
Mizuho Reiterates Neutral Rating on LifeMD Inc (LFMD)
-
Hims and Hers (HIMS) PT Raised to $85 at BTIG
-
Lake Street Capital Markets Starts LifeMD Inc (LFMD) at Buy
-
Mizuho Starts LifeMD Inc (LFMD) at Neutral
-
LifeMD, Inc. (LFMD) Tops Q3 EPS by 21c ; Offers Guidance
-
BTIG Reiterates Buy Rating on LifeMD Inc (LFMD)
-
B.Riley Reiterates Buy Rating on LifeMD Inc (LFMD)
-
BTIG Reiterates Buy Rating on LifeMD Inc (LFMD)
-
These stocks are near-term opportunity to invest in the GLP-1 space

